Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M

INSMED Inc

ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.
2024 ARIKAYCE revenue guidance $340-360M (midpoint 15% growth).
Phase 3 ASPEN (brensocatib) topline data expected latter part of Q2 2024; potential U.S. launch mid-2025.
TPIP Phase 2 PH-ILD study enrollment completed (39 patients); topline data expected Q2 2024.
Phase 3 ENCORE (ARIKAYCE label expansion) topline readout expected 2025; FDA feedback received on ARISE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.